Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glas… Read more
Genomic Vision Société Anonyme (G09) - Total Liabilities
Latest total liabilities as of June 2023: €6.73 Million EUR
Based on the latest financial reports, Genomic Vision Société Anonyme (G09) has total liabilities worth €6.73 Million EUR as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genomic Vision Société Anonyme - Total Liabilities Trend (2013–2022)
This chart illustrates how Genomic Vision Société Anonyme's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genomic Vision Société Anonyme Competitors by Total Liabilities
The table below lists competitors of Genomic Vision Société Anonyme ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
India | ₹99.34 Million |
|
Emmaus Life Sciences Inc
OTCQB:EMMA
|
USA | $80.24 Million |
|
Giant Motorsports Inc
PINK:BZRD
|
USA | $131.52K |
|
CL8 Holdings Ltd
AU:CL8
|
Australia | AU$13.01 Million |
|
Taiton Resources Ltd
AU:T88
|
Australia | AU$279.52K |
|
Hopium SAS
PA:ALHPI
|
France | €21.55 Million |
|
Societe Parisienne d’apports En Capital SPAC SA
PA:MHM
|
France | €3.91 Million |
Liability Composition Analysis (2013–2022)
This chart breaks down Genomic Vision Société Anonyme's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomic Vision Société Anonyme's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomic Vision Société Anonyme (2013–2022)
The table below shows the annual total liabilities of Genomic Vision Société Anonyme from 2013 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | €6.28 Million | +69.56% |
| 2021-12-31 | €3.70 Million | -11.41% |
| 2020-12-31 | €4.18 Million | +75.96% |
| 2019-12-31 | €2.38 Million | -47.65% |
| 2018-12-31 | €4.54 Million | +0.33% |
| 2017-12-31 | €4.52 Million | +42.07% |
| 2016-12-31 | €3.18 Million | -10.44% |
| 2015-12-31 | €3.55 Million | -5.20% |
| 2014-12-31 | €3.75 Million | -22.20% |
| 2013-12-31 | €4.82 Million | -- |